BioNTech gets US agency notice over default on COVID vaccine royalties
The U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine.
If you are not happy with the results below please do another search
The U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine.
Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.
A recent study carried out by researchers at Tulane University and published in the American Journal of Respiratory and Critical Care Medicine unveiled a novel diagnostic tool that can identify Mycobacterium avium complex (MAC) nontuberculous mycobacterial (NTM) infections in as little as two hours.
Despite meeting its primary endpoint in a late-stage generalized myasthenia gravis trial, Roche and Chugai Pharmaceutical’s Enspryng did not demonstrate clinical benefit as expected, the companies announced Thursday.
Following its label expansion earlier this month, Medicare on Thursday said it will now cover the use of Novo Nordisk’s Wegovy in patients with overweight or obesity who have preexisting cardiovascular disease.
The European Union’s medicines regulator has delayed it decision on Eisai and partner Biogen’s Alzheimer’s disease drug that was expected this week, the Japanese company said today.
Stemirna Therapeutics has halted an early stage trial for a new cancer vaccine, two of its trial researchers said, in a fresh setback to the company, which has been grappling with tight funding.
The oral drug, to be sold under the brand name Duvyzat, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD, according to the FDA.
Yesterday the agency classified the recall of privately held Vyaire Medical’s respiratory support devices as most serious and said their use could cause major injuries or death.
“2023 was a banner year for MMC,” shared agency CEO Olga Fleming. “We artfully disrupted everything we touched, including our own brand. We exceeded all business goals, announced new partnerships with disruptive partners, and made significant investments in our people. In 2024 and beyond, we are focused on cultivating a place where people, companies, and brands can thrive to their fullest potential. With these executive appointments and promotions, we are steadfast in our commitment to exceed the loftiest workplace and business expectations, ushering in an era of unparalleled excellence.”